Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent~2. Male or female patients, aged ≥40 years~3. Patient undergoing phacoemulsification~4. Corneal thickness between 450 μm and 600 μm as measured by means of pachymetry~5. Corneal integrity confirmed by means of fluorescein test~6. Adequate pupil dilation assessed at screening~7. Female patients of childbearing potential must have a negative pregnancy test~8. Ability to fully understand all study procedures~Exclusion Criteria:~1. Corneal epithelium integrity not confirmed by fluorescein test~2. History of corneal disease or dystrophy~3. History of ocular trauma with corneal damage~4. History of acute ocular inflammation (including uveitis) in the 6 months prior to screening~5. Previous ocular surgery (including laser treatment)~6. Glaucoma~7. Treatment with an ophthalmic investigational drug in the 3 months prior to screening~8. Treatment with any topical ocular drug within 12 hours before start of cataract surgery other than study drugs and instillation of topical anaesthetic within 10 minutes before start of surgery~9. Treatment with any topical steroid or antibiotic drug in the 7 days prior to cataract surgery~10. Treatment with any systemic steroid or antibiotic drug in the 7 days prior to cataract surgery~11. Known hypersensitivity to levofloxacin, other fluoroquinolones or dexamethasone~12. Pregnant or lactating women~13. Patients who have received any investigational drug during the preceding 30 days or 5 times the plasma half-life, or who have previously participated in this trial

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levofloxacin + Dexamethasone (Type: EXPERIMENTAL): Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery.
- Levofloxacin (Type: ACTIVE_COMPARATOR): Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery.
- Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).